<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761137</url>
  </required_header>
  <id_info>
    <org_study_id>NH004-2</org_study_id>
    <nct_id>NCT00761137</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients</brief_title>
  <acronym>NH004-2</acronym>
  <official_title>A Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroHealing Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NeuroHealing Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the study is to evaluate the safety and potential efficacy of intra-oral
      dissolvable NH004 films to improve the short-term symptoms of sialorrhea (drooling) in
      Parkinson's disease (PD) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NH004 contains the anticholinergic agent tropicamide and is delivered in a convenient product
      form (intra-oral dissolvable thin films) designed for the management of sialorrhea. This
      study is a double blind, placebo-controlled, crossover study of the safety and potential
      efficacy of three doses of of NH004 films for the short-term relief of the symptoms of
      sialorrhea in Parkinson's disease patients.

      A total of up to 36 Parkinson's disease patients will be enrolled in the study in two Phases.
      Phase A will include 12 patients and Phase B up to 24 patients. There will be an interim
      analysis after conclusion of Phase A. In both phases patients will be randomized into one of
      four groups. Each group will have a distinctive sequence for receiving intra-oral dissolvable
      films of 0.3 mg, 1 mg, 3 mg of NH004, or placebo during four visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sialorrhea Visual Analogue Scale (VAS)</measure>
    <time_frame>Before and 120 min after treatment administration</time_frame>
    <description>Saliva buccal assessment was evaluated by an VAS scale before, and 15, 30, 45, 60, 90, and 120 min after treatment administration. Subjects were asked to rate how much saliva they perceived in their buccal cavity on an unmarked 0 to 10 cm line, higher scores meaning greater perceived buccal saliva levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Saliva Volume</measure>
    <time_frame>Before and 75 minutes after treatment administration</time_frame>
    <description>Saliva volume was measured at baseline and 75 minutes after treatment administration. Volumes were measured by using cotton rolls placed near each Stenton duct and below the tongue for 5 minutes; cotton rolls were centrifuged and the volume of saliva determined.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Sialorrhea Secondary to Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Tropicamide placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject received (blinded) each of the 4 drug doses at different visits - 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tropicamide 0.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject received (blinded) each of the 4 drug doses at different visits - 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tropicamide 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject received (blinded) each of the 4 drug doses at different visits - 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tropicamide 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject received (blinded) each of the 4 drug doses at different visits - 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3 mg tropicamide</intervention_name>
    <description>0.3 mg tropicamide in intra-oral thin film</description>
    <arm_group_label>Tropicamide placebo</arm_group_label>
    <arm_group_label>Tropicamide 0.3 mg</arm_group_label>
    <arm_group_label>Tropicamide 1 mg</arm_group_label>
    <arm_group_label>Tropicamide 3 mg</arm_group_label>
    <other_name>NH004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg tropicamide</intervention_name>
    <description>1 mg tropicamide in intra-oral thin film</description>
    <arm_group_label>Tropicamide placebo</arm_group_label>
    <arm_group_label>Tropicamide 0.3 mg</arm_group_label>
    <arm_group_label>Tropicamide 1 mg</arm_group_label>
    <arm_group_label>Tropicamide 3 mg</arm_group_label>
    <other_name>NH004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg tropicamide</intervention_name>
    <description>3 mg tropicamide in intra-oral thin film</description>
    <arm_group_label>Tropicamide placebo</arm_group_label>
    <arm_group_label>Tropicamide 0.3 mg</arm_group_label>
    <arm_group_label>Tropicamide 1 mg</arm_group_label>
    <arm_group_label>Tropicamide 3 mg</arm_group_label>
    <other_name>NH004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0 mg tropicamide</intervention_name>
    <description>0 mg tropicamide (placebo) in intra-oral thin film</description>
    <arm_group_label>Tropicamide placebo</arm_group_label>
    <arm_group_label>Tropicamide 0.3 mg</arm_group_label>
    <arm_group_label>Tropicamide 1 mg</arm_group_label>
    <arm_group_label>Tropicamide 3 mg</arm_group_label>
    <other_name>NH004 (placebo)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with idiopathic Parkinson's disease, according to the United Kingdom Brain
             Bank criteria.

          2. Patients complaining of drooling, with a score of at least 3 in the FLENI Sialorrhea
             scale.

          3. Patient is between 50 and 80 years of age, inclusive.

          4. Male or non-pregnant female. Females of child-bearing potential will be required to
             have undergone a pregnancy test with negative results prior to entry to the study and
             agree to use contraceptive measures for the duration of the study.

          5. Patients must have used the same medication and dose for PD for the last month. No
             changes in the medication for PD are expected during the study.

          6. Patients who can reasonable be expected to be on &quot;on-state&quot; for the duration of the
             testing procedures.

          7. Patients who have a stable response to levodopa for PD.

        Exclusion Criteria:

          1. Pregnant women or women who may become pregnant.

          2. Patients with a diagnosis of depression, schizophrenia or with obvious symptoms of
             these diseases.

          3. Patients with Mini-Mental State Examination (MMSE) score equal to or lower than 26.

          4. Patients who are receiving the following drugs: tricyclic antidepressants, Monoamine
             Oxidase Inhibitors (MAOI's), neuroleptics (antipsychotics), or anticholinergics.

          5. Patients who have taken any of the drugs mentioned in exclusion criteria number 4
             within the last week.

          6. Patients with hypersensitivity to atropine or other anticholinergic drugs.

          7. Patients who have experienced adverse effects as a result of taking anticholinergic
             drugs.

          8. Patients taking hypnotic or other sleep inducing drugs.

          9. Patients with severe urinary or gastrointestinal symptoms.

         10. Patients with significant dental/oral pathology.

         11. Patients with severe dysautonomia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elkan R Gamzu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NeuroHealing Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcelo Merello, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FLENI Hospital, Argentina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FLENI Hospital</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <results_reference>
    <citation>Lloret SP, Nano G, Carrosella A, Gamzu E, Merello M. A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. J Neurol Sci. 2011 Nov 15;310(1-2):248-50. doi: 10.1016/j.jns.2011.05.021. Epub 2011 Jun 1.</citation>
    <PMID>21636098</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <results_first_submitted>August 5, 2011</results_first_submitted>
  <results_first_submitted_qc>September 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2015</results_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sialorrhea</keyword>
  <keyword>drooling</keyword>
  <keyword>excessive salivation</keyword>
  <keyword>parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Sialorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tropicamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Four interventions, subjects were randomly assigned to one of 16 sequences.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>subjects randomly received (blinded) each of the 4 doses at different visits - 0 mg, 0.3 mg, 1mg, 3 mg Drug: Tropicamide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>0.3 mg Tropicamide</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1 mg Tropicamide</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 mg Tropicamide</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>This study was a double-blind, randomized, placebo controlled, two-phased, Latin-square crossover study. Subjects received three single-doses of tropicamide or placebo in random order, with a 7-day washout period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sialorrhea Visual Analogue Scale (VAS)</title>
        <description>Saliva buccal assessment was evaluated by an VAS scale before, and 15, 30, 45, 60, 90, and 120 min after treatment administration. Subjects were asked to rate how much saliva they perceived in their buccal cavity on an unmarked 0 to 10 cm line, higher scores meaning greater perceived buccal saliva levels.</description>
        <time_frame>Before and 120 min after treatment administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tropicamide - Placebo</title>
            <description>Each subject randomly received blinded a placebo thin film containing no active drug ingredient</description>
          </group>
          <group group_id="O2">
            <title>Tropicamide - 0.3 mg</title>
            <description>Each subject randomly received blinded a thin film containing 0.3 mg active drug ingredient</description>
          </group>
          <group group_id="O3">
            <title>Tropicamide - 1 mg</title>
            <description>Each subject randomly received blinded a thin film containing 1 mg active drug ingredient</description>
          </group>
          <group group_id="O4">
            <title>Tropicamide 3 mg</title>
            <description>Each subject randomly received blinded a thin film containing 3 mg active drug ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Sialorrhea Visual Analogue Scale (VAS)</title>
          <description>Saliva buccal assessment was evaluated by an VAS scale before, and 15, 30, 45, 60, 90, and 120 min after treatment administration. Subjects were asked to rate how much saliva they perceived in their buccal cavity on an unmarked 0 to 10 cm line, higher scores meaning greater perceived buccal saliva levels.</description>
          <units>cm on VAS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.54"/>
                    <measurement group_id="O2" value="-1.08" spread="0.54"/>
                    <measurement group_id="O3" value="-1.53" spread="0.52"/>
                    <measurement group_id="O4" value="-0.81" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was analyzed by a mixed-effects ANOVA model employing “subject” as a random factor as well as “visit” and “treatment” as fixed factors. Intention-to-treat (ITT) sample was analyzed. Unweighted means and their 95% Confidence Interval (CI) are reported, which represent treatment group means adjusted for the effect of visit and removing the intra-subject variability. For all analyses, significance level was set at 5%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Saliva Volume</title>
        <description>Saliva volume was measured at baseline and 75 minutes after treatment administration. Volumes were measured by using cotton rolls placed near each Stenton duct and below the tongue for 5 minutes; cotton rolls were centrifuged and the volume of saliva determined.</description>
        <time_frame>Before and 75 minutes after treatment administration</time_frame>
        <population>Percentage saliva volume change was determined in the last seven (7) patients enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Tropicamide - Placebo</title>
            <description>Each subject randomly received blinded a placebo thin film containing no active drug ingredient</description>
          </group>
          <group group_id="O2">
            <title>Tropicamide - 0.3 mg</title>
            <description>Each subject randomly received blinded a thin film containing 0.3 mg active drug ingredient</description>
          </group>
          <group group_id="O3">
            <title>Tropicamide - 1 mg</title>
            <description>Each subject randomly received blinded a thin film containing 1 mg active drug ingredient</description>
          </group>
          <group group_id="O4">
            <title>Tropicamide 3 mg</title>
            <description>Each subject randomly received blinded a thin film containing 3 mg active drug ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Saliva Volume</title>
          <description>Saliva volume was measured at baseline and 75 minutes after treatment administration. Volumes were measured by using cotton rolls placed near each Stenton duct and below the tongue for 5 minutes; cotton rolls were centrifuged and the volume of saliva determined.</description>
          <population>Percentage saliva volume change was determined in the last seven (7) patients enrolled.</population>
          <units>percentage change of saliva volume</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" lower_limit="-27" upper_limit="17"/>
                    <measurement group_id="O2" value="-27" lower_limit="-48" upper_limit="-6"/>
                    <measurement group_id="O3" value="-33" lower_limit="-60" upper_limit="-7"/>
                    <measurement group_id="O4" value="-20" lower_limit="-33" upper_limit="-7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>subjects received (blinded) each of the 4 doses at different visits - 0 mg, 0.3 mg, 1mg, 3 mg Drug: Tropicamide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Katzman</name_or_title>
      <organization>NeuroHealing Pharmaceuticals</organization>
      <phone>617-965-0872</phone>
      <email>info@neurohealing.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

